Capstone Holding Corp. lowers convertible note conversion price to $1.00
LONDON - LMR Partners LLP has disclosed a 2.997% interest in Mural Oncology plc, representing a holding of 516,418 shares, according to a regulatory filing with the Irish Takeover Panel. The disclosure, made under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, indicates that LMR Partners had acquired 16,418 ordinary shares at a price of £2.76 per unit on Wednesday.
The investment firm’s position in the biotechnology company was reported on Thursday, with no additional interests or short positions in other classes of relevant securities of Mural Oncology disclosed. The announcement does not indicate any dealings in cash-settled or stock-settled derivative transactions by LMR Partners.
The disclosure is a routine regulatory requirement for entities holding interests in relevant securities representing 1% or more, and it provides transparency in the context of potential takeover activities. The information is based on a press release statement and does not suggest any future acquisition or disposal intentions by LMR Partners regarding Mural Oncology.
Mural Oncology plc has not been identified as being involved in any other party to the offer, and LMR Partners has not disclosed any indemnity or option arrangements, agreements, or understandings relating to the voting rights of Mural Oncology’s relevant securities.
This development comes amid typical market activities where investment firms adjust their holdings in various companies. Investors and market observers often monitor such disclosures for insights into investment firm strategies and potential market movements.
The contact for the disclosure is Ben Sheridan, with a telephone number provided for inquiries. The regulatory disclosure requirements aim to ensure a fair and transparent market, particularly during sensitive periods such as takeovers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.